Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis
References (42)
- et al.
Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (Group I) and review of 78 previously described necropsy patients (Group II)
Am J Med
(1977) - et al.
Thallium scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients
Am J Med
(1980) - et al.
Non-invasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. II. Clinical methodology and feasibility
Am J Cardiol
(1978) - et al.
Thallium-201 myocardial scintigraphy
Am Heart J
(1985) - et al.
Noninvasive detection and localization of coronary stenoses in patients: comparison of resting dipyridamole and exercise thallium-201 myocardial perfusion imaging
Am Heart J
(1982) - et al.
Chest pain in the presentation of sarcoidosis
Chest
(1976) - et al.
Hypothesis. Is congestive cardiomyopathy caused by a hyperreactive myocardial microcirculation (microvascular spasm)
Am J Cardiol
(1982) - et al.
Myocardial degeneration in cardiac sarcoidosis.Histochemical and electron microscopic studies
Am Heart J
(1965) Different responsiveness of a variety of isolated dog arteries to prostaglandin D2
Prostaglandins
(1982)- et al.
The inconsistent pattern of thallium defects: a due to the false positive perfusion scintigram
Am J Cardiol
(1981)
Exercise thallium-201 myocardial scintigraphy in women: correlation with coronary arteriography
Am J Cardiol
The cardiomyopathies and myocarditis
Sarcoid heart disease
J R Coll Physicians
Cardiac sarcoidosis: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis
Circulation
Clinicopathological study on fatal myocardial sarcoidosis
Ann NY Acad Sci
Utility of endomyocardial biopsy in the diagnosis of the cardiac sarcoidosis
Chest
Assessment of sarcoid heart disease. A study of 37 patients with thoracic sarcoidosis
The use of 201 thallium for myocardial perfusion imaging in sarcoid heart disease
Chest
Redistribution on the thallium scan in sarcoidosis: concise communication
J Nucl Med
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma
N Engl J Med
Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis
N Engl J Med
Cited by (86)
Radionuclide Assessment of Sarcoidosis
2023, Cardiology ClinicsMachine learning predicting mortality in sarcoidosis patients admitted for acute heart failure
2022, Cardiovascular Digital Health JournalMyocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review
2022, Autoimmunity ReviewsCitation Excerpt :According to several necropsy reports, about 20-28% of sarcoid patients in the United States and the United Kingdom showed histological evidence of cardiac granuloma with even a higher (50-78%) frequency among Japanese patients [5,6]. However, cardiac sarcoidosis (CS) is often unrecognized ante mortem and clinical studies discovered only a small amount of cardiac involvement (2-7%) in sarcoidosis patients [7], while occult involvement at autopsy was detected in over 20% of patients [8–11]. Table 1 lists studies reporting on cardiac involvement among sarcoidosis patients.
Imaging of myocarditis and inflammatory cardiomyopathies
2019, Archives of Cardiovascular DiseasesCitation Excerpt :Whenever possible, perfusion imaging should be combined with 18F-FDG to allow identification of specific patterns suggestive of either active or quiescent disease. Evidence of myocardial perfusion abnormalities associated with cardiac sarcoidosis, and their reversibility after pharmacological vasodilation, suggesting that microvascular alterations may be a possible cause of perfusion abnormalities in addition to scar tissue, were reported with thallium by single photon emission tomography decades ago [74–76]. Indeed, the reversibility of perfusion defects after dipyridamole infusion was correlated with their improvement after corticosteroid therapy, suggesting that the acute response under vasodilation was a good predictor of steroid efficacy, and thus could help to select those patients with cardiac sarcoidosis who might benefit most from corticotherapy [77].
Cardiac Sarcoidosis: A Review of Contemporary Challenges in Diagnosis and Treatment
2018, American Journal of the Medical SciencesCitation Excerpt :Some authors had proposed that microvascular vasoconstriction may be the pathogenic mechanism of these perfusion defects. This is supported by reversibility of perfusion defects between postinjection rest and delayed images.62 The relationship between the abnormal thallium perfusion defects and clinical cardiac dysfunction has not been elucidated and evidence is lacking in this field.